Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
19.87
+0.21 (1.09%)
At close: May 16, 2025, 4:00 PM
19.88
+0.02 (0.08%)
After-hours: May 16, 2025, 4:05 PM EDT
Genmab Revenue
Genmab had revenue of 715.00M DKK in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to 21.64B, up 51.92% year-over-year. In the year 2024, Genmab had annual revenue of 21.53B with 30.67% growth.
Revenue (ttm)
21.64B DKK
Revenue Growth
+51.92%
P/S Ratio
3.90
Revenue / Employee
8,067,860 DKK
Employees
2,682
Market Cap
12.23B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GMAB News
- 3 days ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 5 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 9 days ago - Genmab Announces Financial Results for the First Quarter of 2024 - GlobeNewsWire
- 15 days ago - Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - Business Wire
- 4 weeks ago - Genmab's Outlook Beyond Darzalex's Patent Cliff - Seeking Alpha
- 4 weeks ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - GlobeNewsWire
- 5 weeks ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 5 weeks ago - Transactions In Connection with Share Buy-back Program - GlobeNewsWire